EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN - August 7, 2025 - Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA ™ device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year. “For decades, clinicians without access to BVA have been forced to estimate a patient’s blood volume status using indirect, often invasive, or imprecise methods,” said Michael Feldschuh, Daxor’s President and CEO. “This critical knowledge gap has impacted treatment decisions across numerous medical specialties. Daxor’s next generation BVA device changes the game by delivering even faster, precise blood volume data anywhere there is access to a laboratory - from the hospi…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Daxor Corporation
DXRNASDAQEQUITYCurrent
Other Events
Item 8.01 – Other Events Daxor Corporation, the global leader in blood volume measurement technology, announces FDA 510(k) clearance for its next-generation rapid, portable lab-based Blood Volume Analysis (BVA) system. The new Daxor BVA™ device quantifies a patient’s blood volume against patient-specific norms, enabling precise care, significantly improving outcomes for millions of patients each year.…
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01 – Other Events
Daxor
Corporation, the global leader in blood volume measurement technology, announces FDA 510(k) clearance for its next-generation rapid,
portable lab-based Blood Volume Analysis (BVA) system. The new Daxor BVA™ device quantifies a patient’s blood volume against
patient-specific norms, enabling precise care, significantly improving outcomes for millions of patients each year.
The
press release issued is attached to this filing as Exhibit 99.1